Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17A | Q9UEE5 | 6/20 | 0.34 |
| ▸ | STK17B | O94768 | 1/20 | 0.34 |
| ▸ | NMT2 | O60551 | 1/20 | 0.33 |
| ▸ | NMT1 | P30419 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 3/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21550741 | 1.00 | STK17A (0.34) | STK17ASTK17BNMT2NMT1CCNT1 | |
| SCHEMBL29891096 | 0.80 | SLC6A4 (0.41) | SYK | |
| SCHEMBL30931824 | 0.80 | CARM1 (0.36) | CD274CARM1PRMT6 | |
| SCHEMBL21551258 | 0.80 | CARM1 (0.36) | CD274CARM1PRMT6 | |
| SCHEMBL21564351 | 0.79 | CARM1 (0.35) | CD274CARM1PRMT6 | |
| SCHEMBL21551391 | 0.74 | LRRK2 (0.39) | CHEK1CNR2PRMT6 | |
| SCHEMBL29892246 | 0.74 | LRRK2 (0.39) | CHEK1CNR2PRMT6 | |
| SCHEMBL21551365 | 0.73 | FURIN (0.41) | — | |
| SCHEMBL29928375 | 0.73 | FURIN (0.41) | — | |
| SCHEMBL21550748 | 0.73 | FURIN (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112384509-B | Furin inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-04-30 | — | — | CN | claimed |
| EP-4058021-A1 | SMALL MOLECULE FURIN INHIBITORS FOR TREATING INFECTIOUS DISEASES | BP Asset V, Inc. (US) | 2022-09-21 | — | — | EP | claimed |
| CN-112384509-B | Furin inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20230011571-A1 | SMALL MOLECULE FURIN INHIBITORS FOR TREATING INFECTIOUS DISEASES | BP ASSET V, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20220315556-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315556-A1 | FURIN INHIBITORS | FURIN, TGFB1, PCSK7 | STK17A 522/4885STK17B 789/4885NMT2 206/4885 |
| US-20230011571-A1 | SMALL MOLECULE FURIN INHIBITORS FOR TREATING INFECTIOUS DISEASES | FURIN, LGMN, PLAU | STK17A 409/4885STK17B 861/4885NMT2 1334/4885 |
| US-11773078-B2 | Furin inhibitors | FURIN, TGFB1, PCSK7 | STK17A 522/4885STK17B 789/4885NMT2 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.